Bad News for Hims & Hers, Ro, and Noom

  • Eli Lilly’s obesity and diabetes drugs Zepbound and Mounjaro no longer in shortage
  • FDA resolution affects copycat drug companies like Hims & Hers, Ro, and Noom
  • Lilly to invest $4.5 billion in Indiana manufacturing center for clinical trials

Eli Lilly’s obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage according to the FDA. This is good news for Lilly but bad news for companies like Hims & Hers, Ro, and Noom that have capitalized on the shortages. Novo Nordisk’s rival drugs Ozempic and Wegovy remain on the FDA shortage list. Lilly plans to invest $4.5 billion in an Indiana manufacturing center for clinical trials.

Factuality Level: 8
Factuality Justification: The article provides accurate information about the resolution of shortages for Eli Lilly’s drugs Zepbound and Mounjaro, mentions the impact on competitors like Hims & Hers Health and Ro, and includes relevant details about the FDA’s role in drug copying. It also reports on Lilly’s plans to invest in manufacturing and Novo Nordisk’s ongoing shortages. The article is mostly factual with a minor focus on stock market reactions.
Noise Level: 2
Noise Justification: The article provides relevant information about the resolution of shortages for Eli Lilly’s drugs Zepbound and Mounjaro, but also includes some irrelevant details such as stock market reactions and unrelated information about Novo Nordisk’s drugs Ozempic and Wegovy. The article could have focused more on the implications of the resolution of the shortage and its impact on the industry without mentioning specific stock prices.
Public Companies: Eli Lilly (LLY), Novo Nordisk (NVO)
Private Companies: Hims & Hers Health,Ro,Noom
Key People:

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Yes
Financial Rating Justification: The article discusses the resolution of shortages for Eli Lilly’s blockbuster drugs, which impacts the pharmaceutical company’s supply issues and affects competitors like Hims & Hers Health and Noom. It also mentions stock movements in response to the news.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.
Deal Size: 4500000000
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks

Reported publicly: www.barrons.com